LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Emergency 3-Dimensional-Printed Devices for Splitting Ventilators in Lungs With Different Compliances: An In Vitro Study.

    Frizzera-Borges, Marcelo / Frizzera, Fausto / Lemos, Jório B M / Carraretto, Antônio R

    A&A practice

    2021  Band 15, Heft 3, Seite(n) e01392

    Abstract: Ventilator shortages occurred due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This in vitro study evaluated the effectiveness of 3-dimensional (3D)-printed splitters and 3D-printed air flow limiters (AFL) in delivering ... ...

    Abstract Ventilator shortages occurred due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This in vitro study evaluated the effectiveness of 3-dimensional (3D)-printed splitters and 3D-printed air flow limiters (AFL) in delivering appropriate tidal volumes (TV) to lungs with different compliances. Groups were divided according to the size of the AFL: AFL-4 was a 4-mm device, AFL-5 a 5-mm device, AFL-6 a 6-mm device, and no limiter (control). A ventilator was split to supply TV to 2 artificial lungs with different compliances. The AFL improved TV distribution.
    Mesh-Begriff(e) COVID-19/epidemiology ; COVID-19/therapy ; Emergency Medical Services/methods ; Humans ; Lung/physiology ; Lung Compliance/physiology ; Male ; Printing, Three-Dimensional ; Tidal Volume/physiology ; Ventilators, Mechanical/supply & distribution
    Sprache Englisch
    Erscheinungsdatum 2021-03-09
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2575-3126
    ISSN (online) 2575-3126
    DOI 10.1213/XAA.0000000000001392
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011.

    Bognar, Cinthia Leite Frizzera Borges / Simon, Sergio Daniel / Gansl, Rene Claudio / Abramoff, Roberto / Aisen, Marcelo / Lopes Junior, Gilberto de Lima / Smaletz, Oren / Peres, Stela Verzinhasse / Tabacof, Jacques

    Einstein (Sao Paulo, Brazil)

    2015  Band 13, Heft 2, Seite(n) 215–220

    Abstract: Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment.: Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a ... ...

    Abstract Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment.
    Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a reference general hospital and a private oncology clinic, who received erlotinib from 2005 to 2011. Statistical analysis was performed and we evaluated demographic data and response to treatment, by correlating the results of this first cohort published in Brazil with results of current literature.
    Results: A total of 44 patients were included; 65.9% were diagnosed with adenocarcinoma, and 63.6% had metastatic disease. The mean age was 63.3 years. The median follow-up was 47.9 months. Epidermal growth factor receptor mutation screening was performed in 22.7% of patients (n=10), with mutation present in 30% of patients. The median overall survival was 46.3 months, and there was a higher probability of survival at 60 months for females compared to males (29.4% versus 15.8%; p=0.042). The other variables did not present significant statistical difference.
    Conclusion: We collected the largest cohort of patients with non-small-cell lung cancer who have used erlotinib in Brazil to date, and demonstrated that outcomes of patients treated at our clinic during the study period were consistent with the results of current literature in similar patients.
    Mesh-Begriff(e) Adenocarcinoma/drug therapy ; Adenocarcinoma/mortality ; Adenocarcinoma/secondary ; Adenocarcinoma of Lung ; Adult ; Aged ; Aged, 80 and over ; Brazil ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/secondary ; ErbB Receptors/genetics ; Erlotinib Hydrochloride ; Female ; Follow-Up Studies ; Hospitals, General ; Hospitals, Proprietary ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Lung Neoplasms/secondary ; Male ; Middle Aged ; Mutation/genetics ; Protein Kinase Inhibitors/therapeutic use ; Quinazolines/therapeutic use ; Retrospective Studies ; Sex Distribution ; Survival Rate ; Treatment Outcome
    Chemische Substanzen Protein Kinase Inhibitors ; Quinazolines ; Erlotinib Hydrochloride (DA87705X9K) ; ErbB Receptors (EC 2.7.10.1)
    Sprache Portugiesisch
    Erscheinungsdatum 2015-07-08
    Erscheinungsland Brazil
    Dokumenttyp Journal Article
    ZDB-ID 2418293-X
    ISSN 2317-6385 ; 1679-4508
    ISSN (online) 2317-6385
    ISSN 1679-4508
    DOI 10.1590/S1679-45082015AO3326
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011

    Cinthia Leite Frizzera Borges Bognar / Sergio Daniel Simon / Rene Claudio Gansl / Roberto Abramoff / Marcelo Aisen / Gilberto de Lima Lopes Junior / Oren Smaletz / Stela Verzinhasse Peres / Jacques Tabacof

    Einstein (São Paulo), Vol 13, Iss 2, Pp 215-220

    Abstract: ABSTRACT Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment. Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a ... ...

    Abstract ABSTRACT Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment. Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a reference general hospital and a private oncology clinic, who received erlotinib from 2005 to 2011. Statistical analysis was performed and we evaluated demographic data and response to treatment, by correlating the results of this first cohort published in Brazil with results of current literature. Results: A total of 44 patients were included; 65.9% were diagnosed with adenocarcinoma, and 63.6% had metastatic disease. The mean age was 63.3 years. The median follow-up was 47.9 months. Epidermal growth factor receptor mutation screening was performed in 22.7% of patients (n=10), with mutation present in 30% of patients. The median overall survival was 46.3 months, and there was a higher probability of survival at 60 months for females compared to males (29.4% versus 15.8%; p=0.042). The other variables did not present significant statistical difference. Conclusion: We collected the largest cohort of patients with non-small-cell lung cancer who have used erlotinib in Brazil to date, and demonstrated that outcomes of patients treated at our clinic during the study period were consistent with the results of current literature in similar patients.
    Schlagwörter Carcinoma pulmonar de células não pequenas ; Genes erbB-1 ; Receptor do fator de crescimento epidérmico ; Inibidores de proteínas quinases ; Antineoplásicos ; Medicine ; R
    Thema/Rubrik (Code) 610 ; 616
    Sprache Englisch
    Verlag Instituto Israelita de Ensino e Pesquisa Albert Einstein
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang